Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction

Journal of General Internal Medicine

Volumn 23, Issue 2, 2008, Pages 115-121

  Akincigil, Ayse ^a,b   Bowblis, John R ^b   Levin, Carrie ^b   Jan, Saira ^c,d   Patel, Minalkumar ^e   Crystal, Stephen ^b  

^a RUTGERS UNIVERSITY   (United States)

^b The State University of New Jersey   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY   (United States)

^e Horizon Healthcare Insurance Company of New York   (United States)

Author keywords

Acute myocardial infarction; Adherence; Angiotensin converting enzyme inhibitors (ACEI); Beta blockers; Secondary prevention

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARTEOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; LABETALOL; LISINOPRIL; METOPROLOL; MOEXIPRIL; NADOLOL; PENBUTOLOL; PERINDOPRIL; PINDOLOL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; SOTALOL; TIMOLOL; TRANDOLAPRIL; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE PLANNING; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PHARMACY; PROPORTIONAL HAZARDS MODEL; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 38949167144     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0351-9     Document Type: Article

References (25)

1. National Institutes of Health; National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institutes of Health; 2004
2. Everly MJ, Heaton PC, Cluxton RJ, Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004;38(2):286-93.
3. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115(6):473-9.
4. Smith SC, Jr, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104(13):1577-9.
5. Williams SC, Schmaltz SP, Morton DJ, Koss RG, Loeb JM. Quality of care in U.S. hospitals as reflected by standardized measures, 2002-2004. N Engl J Med. 2005;353(3):255-64.
6. Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the Medicare health care quality improvement program. Arch Intern Med. 2003;163(12):1430-9.
7. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40(9):1589-95.
8. Mitra S, Findley K, Frohnapple D, Mehta JL. Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. Clin Cardiol. 2002;25(1):16-8.
9. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145(3):438-44.
10. Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf. 2004;13(11):761-6.
11. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21(6):485-8.
12. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147-52.
13. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117(2):73-81.
14. Gregoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002;55(7):728-35.
15. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-12.
16. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99-104.
17. United State Census Bureau. Census 2000 Summary File 3 (SF3)-Sample Data. Available at http://factfinder.census.gov/servlet/DatasetMainPageServlet?_program=DEC&_lang=en.
18. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995.
19. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
20. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res. 1997;34(1):248-53.
21. Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152(3):451-58.
22. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164(2):203-9.
23. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. The Pharmacological Basis of Therapeutics, 11th ed. New York, NY: McGraw-Hill; 2006.
24. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care. 2006;44(5):471-7.
25. National Committee on Quality Assurance. HEDIS 2005, vol 2: Technical Specifications. Washington, DC: National Committee on Quality Assurance; 2005.